HRT in India: Options, Cost, Brands and Real Risks

• HRT is the most effective treatment for hot flushes, night sweats, sleep disruption and vaginal symptoms in suitable women.
• For most women who start within 10 years of their last period and before age 60, the benefits outweigh the small risks.
• Transdermal estrogen (patch or gel) carries a lower clot risk than tablets and is now the preferred route for many women.
• If you still have a uterus you also need a progestogen; if you've had a hysterectomy, estrogen alone is enough.
• A typical patch-plus-progesterone regimen in India costs roughly 2,500-4,500 per month; vaginal estrogen for dryness alone is cheaper.
• There is no fixed 5-year stop rule any more; duration is reviewed yearly with your doctor based on benefit and risk.

HRT suits women with moderate-to-severe menopause symptoms who fit certain clinical criteria where the benefit-risk balance is favourable. The main reasons doctors prescribe it are: troublesome vasomotor symptoms (hot flushes and night sweats that wreck sleep and daily function); genitourinary syndrome of menopause (vaginal dryness, soreness, painful sex, recurrent UTIs and urinary urgency, though local vaginal estrogen is usually preferred when these are the only symptoms); prevention of osteoporosis in women at real fracture risk who can't take bone-specific drugs; and management of early menopause or premature ovarian insufficiency, where HRT is typically continued to the natural menopause age of around 51.

The standard framework is the timing hypothesis, or window of opportunity. Women within 10 years of their final period and under 60 have a favourable profile: clear benefit for symptoms, bone density and quality of life, with only a small absolute rise in breast cancer, clot and stroke risk. Starting much later (more than 10 years past menopause or after 60) shifts the balance, because older blood vessels with established narrowing don't get the same protective effect, so cardiovascular risk becomes less favourable. The Indian Menopause Society and international bodies support starting within this window when there's a clear indication, rather than reflexively avoiding it.

Absolute contraindications to systemic HRT include current or recent breast or endometrial cancer, active or recent venous thromboembolism (DVT or pulmonary embolism in the last 1-2 years), active liver disease, undiagnosed vaginal bleeding (which must be investigated first), recent heart attack or unstable angina, and uncontrolled high blood pressure. Relative cautions, which mean an individual discussion rather than an automatic no, include a strong family history of breast cancer, migraine with aura, previously treated clots, high triglycerides and gallbladder disease. The decision is best made with a menopause-aware gynaecologist who can weigh your specific picture. For the broader symptom map, see perimenopause symptoms in Indian women.

HRT comes in two main forms depending on whether you still have a uterus. Women who've had a hysterectomy can take estrogen alone, because there's no womb lining to be over-stimulated. Women who still have a uterus need estrogen plus a progestogen (combined HRT), because estrogen on its own thickens the womb lining and raises the risk of endometrial cancer over time. The progestogen can be given cyclically (estrogen daily plus progestogen for 12-14 days a month, producing a regular monthly bleed) or continuously (both daily, no planned bleed but some irregular spotting in the first 3-6 months that usually settles).

Cyclical combined HRT is usually chosen for women still having periods or within the first 1-2 years after their last period, because the womb lining responds best to a cyclical pattern at that stage. Continuous combined HRT suits women more than 1-2 years past their final period, whose lining has thinned and stays stable on a steady low dose without bleeding. The switch from cyclical to continuous is usually made about 1-2 years after the final period.

Estrogen-only therapy is simpler: daily estrogen by your chosen route, no progestogen needed. It has a slightly more favourable risk profile than combined HRT. Local vaginal estrogen (creams, tablets, rings) is a separate category used only for vaginal and urinary symptoms; absorption into the bloodstream is minimal, so no progestogen is needed even with an intact uterus. It is covered in detail in the guides to vaginal atrophy in menopause and vaginal estrogen cream. Tibolone (Livial, roughly 800-1,500 per month in India) is a synthetic steroid with weak estrogen, progestogen and androgen activity used as a combined-HRT alternative, sometimes chosen when low libido is a particular concern.

How estrogen enters the body matters for safety. Oral estrogen passes through the liver first, where it raises clotting factors, C-reactive protein and triglycerides and changes gallbladder cholesterol handling. These liver effects are what drive the clot risk (roughly 2-3 times baseline with tablets), the higher gallstone risk and part of the cardiovascular profile.

Transdermal estrogen (patches, gels, sprays) is absorbed through the skin straight into the circulation, bypassing that first liver pass. Clotting-factor changes are minimal, clot risk is close to baseline, and gallbladder and triglyceride effects are much smaller. The benefits on bone, vaginal tissue and brain are similar to tablets. For this reason, transdermal is now the preferred route for most women in Indian and international practice, especially anyone with cardiovascular, clotting or gallbladder risk factors, or anyone needing a higher dose. Tablets remain reasonable for younger perimenopausal women who prefer them and have no specific risk factors.

Transdermal options in India include estradiol patches (Climara, Estraderm and similar, applied weekly or twice weekly, around 1,500-3,500 per month) and estradiol gel (Oestrogel, Sandrena, Divigel, applied daily to a small skin area, around 1,500-3,000 per month). Both give steady levels without the peaks and troughs of tablets. Patch stock varies by city; large Apollo, Cloudnine, Manipal and AIIMS pharmacies usually carry them, while smaller towns may need to order through a metro pharmacy or platforms like 1mg, PharmEasy or Netmeds. Oral options include estradiol (Estrofem 1 mg/2 mg, around 500-1,000 per month) and conjugated equine estrogen (Premarin 0.3-1.25 mg, around 800-1,500). Combination tablets and patches that already include progestogen are covered below.

If you have a uterus, the progestogen is essential to protect the womb lining, and the type you use affects both how you feel and the wider risk profile. Micronised progesterone (Susten in India, 100 mg or 200 mg capsules taken at bedtime; around 600-1,200 per month for HRT use) is structurally identical to your natural hormone and has the kindest side-effect profile, with little effect on mood or breast tenderness and a mild, usually welcome, sedative effect at night. It is the preferred progestogen in current practice and is widely available. For more on this molecule, see the progesterone cream guide.

Synthetic progestogens (progestins) include medroxyprogesterone acetate (Provera, around 200-500 per month, used in the original WHI trial), norethisterone, dydrogesterone (Duphaston, around 500-1,000 per month, long familiar to Indian gynaecologists), and the levonorgestrel released by the Mirena intrauterine system. They have somewhat different metabolic profiles, and the choice comes down to tolerability and individual factors.

The Mirena IUS is a neat option for many women: it delivers progestogen straight to the womb lining with very little reaching the bloodstream, lasts 5 years from a single fitting, and you then take only estrogen separately. The device plus fitting costs about 15,000-22,000 one-time at major Indian hospitals, which works out to roughly 300-400 per month over its life, very cost-effective. It is especially useful in late perimenopause when you may also want contraception and heavy-bleeding control; the broader options are covered in the guide to contraception in perimenopause. Single combined products that pair estrogen and progestogen in one tablet or patch (such as Activelle, Femoston and Kliogest, around 1,500-3,000 per month) simplify the routine and can improve adherence. Choosing between separate components and a combination product is largely about preference and cost. For background on the Indian context, see hormone therapy facts.

A quick map of the Indian market helps you budget and find products locally. The figures below are approximate retail prices at major chains (Apollo Pharmacy, MedPlus, 1mg, PharmEasy) and vary by city and pharmacy; insurance or hospital schemes, where available, cut out-of-pocket cost considerably.

Estrogen-only tablets: Estrofem 1 mg/2 mg (estradiol, around 500-1,000 per month), Premarin 0.625 mg (conjugated equine estrogens, around 800-1,500). Estrogen transdermal: Climara patch (estradiol 25/50/100 mcg, weekly, 2,000-3,500 per month), Estraderm-type patch (twice weekly, 1,500-3,000), Oestrogel (estradiol gel, 1,500-2,500). Single-product combined HRT: Activelle (estradiol 1 mg plus norethisterone 0.5 mg, continuous, around 1,500-2,500), Femoston (estradiol plus dydrogesterone, around 1,500-3,000), Kliogest (around 1,500-2,500). Tibolone: Livial (around 800-1,500 per month).

Separate progestogen when estrogen is taken alone: Susten (micronised progesterone, around 600-1,200 per month for combined use), Duphaston (dydrogesterone, 500-1,000), Provera (medroxyprogesterone, 200-500). Mirena IUS: around 15,000-22,000 one-time plus fitting, lasting 5 years. Vaginal estrogen for dryness alone: Vagifem-type tablets (around 1,500-3,500 per month), Premarin vaginal cream (800-1,500), local estriol cream (400-1,000). A typical combined transdermal regimen (an estradiol patch plus oral micronised progesterone) comes to roughly 2,500-4,500 per month: meaningful but manageable for most middle-class families, and often far less costly than untreated symptoms in lost sleep, productivity and quality of life. Many private insurance plans cover part of HRT, and AIIMS and other government hospital outpatient departments offer subsidised access for eligible patients.

Starting HRT involves a short workup, a deliberate regimen choice, and a review at three months to confirm the dose suits you. The pre-treatment workup usually covers a careful personal and family history (breast cancer, heart disease, clots, gallbladder and liver disease), blood pressure, breast and pelvic examination, basic bloods (fasting lipids, glucose or HbA1c, liver and kidney function), a baseline mammogram if you haven't had one recently, and a pelvic ultrasound to record baseline womb-lining thickness if you have a uterus.

A common starting regimen for a perimenopausal woman aged 45-52 with significant hot flushes and an intact uterus is transdermal estradiol (a 50 mcg weekly patch or daily gel) plus oral micronised progesterone 200 mg at bedtime for 12 days a month (cyclical). For a postmenopausal woman aged 52-60, more than 1-2 years past her last period, a typical choice is a 50 mcg estradiol patch plus 100 mg micronised progesterone daily (continuous combined). After a hysterectomy, estradiol alone is enough.

Expect hot flushes to ease within 2-4 weeks, sleep to improve over a similar period, and mood and vaginal symptoms to settle over 4-8 weeks. Common early side effects include breast tenderness (usually gone within 2-3 months), mild nausea with tablets (less with patches), some irregular spotting in the first 3-6 months of combined HRT, and bloating or minor headaches. Most settle with time or a small change of dose or formulation; persistent troublesome effects are a reason to adjust the regimen rather than abandon treatment. The three-month review checks symptom response, side effects and blood pressure; baseline bloods don't usually need repeating unless something specific arises.

After the three-month review, monitoring settles into an annual check unless something changes. The yearly review covers symptoms (whether you still need the current dose or could reduce it), side effects, blood pressure, breast examination, a mammogram if due, a pelvic examination, and a conversation about continuing. For women with a uterus, a pelvic ultrasound is done if there's any abnormal bleeding; routine annual scans aren't needed on stable combined HRT without bleeding.

Advice on how long to stay on HRT has changed a lot. The old rule to stop at five years came from a narrow early reading of the WHI trial and is no longer the consensus. Current guidance from the Indian Menopause Society and major international bodies is that there is no arbitrary time limit; the decision to continue depends on ongoing symptom benefit, indications and risk-benefit balance, reviewed each year. Many women stay on HRT for 5-10 years through the natural symptom window, and some continue longer when benefits persist and the risk profile remains favourable.

When you do decide to stop, a gradual taper over 3-6 months is generally preferred over stopping abruptly, to limit rebound symptoms. A patch, for example, might step down from 50 mcg twice weekly to 25 mcg, then to once weekly, then off, with the progestogen adjusted to match. Vaginal symptoms can persist or return after stopping systemic HRT and may need ongoing low-dose vaginal estrogen separately. Some women find symptoms return and choose to restart; that is a reasonable choice, not a failure. Think of HRT as part of ongoing menopause care with periodic reassessment, rather than a fixed course.

An honest look at risk is the heart of informed choice. The biggest worry is breast cancer. The WHI combined-HRT arm (conjugated equine estrogen plus medroxyprogesterone) showed an absolute increase of roughly 1 extra case per 1,000 women per year after about 5 years of use. The estrogen-only arm, in women after hysterectomy, showed no increase and possibly a slight decrease. Later observational data have refined this: the small rise appears after 3-5 years, falls again after stopping, is slightly lower with transdermal than oral estrogen and with micronised progesterone than synthetic progestogens, and is comparable in size to other modest factors like one alcoholic drink a day or being moderately overweight. If you want the wider screening picture, see breast cancer screening in India.

Cardiovascular risk has been reassessed since the original WHI alarm. Women starting HRT within 10 years of menopause and under 60 have neutral or possibly slightly favourable heart outcomes, while starting much later may bring small increases. Transdermal estrogen has a more favourable profile than tablets. Clot (venous thromboembolism) risk rises 2-3 times with oral estrogen (an absolute increase of about 2-3 cases per 1,000 women per year) but is minimal or unchanged with transdermal. Stroke risk is slightly raised with tablets and less so with patches.

Other points: endometrial cancer is not increased with appropriate combined HRT, or with estrogen alone after hysterectomy, but unopposed estrogen in a woman with a uterus clearly raises that risk, which is exactly why the progestogen is mandatory. Ovarian cancer risk rises slightly with long-term use, in absolute terms small. Against these sit substantial benefits: relief of hot flushes and night sweats, better sleep, steadier mood, improved vaginal comfort, and reduced bone loss and fracture risk; bone protection is covered in the guide to osteoporosis in Indian women. For most women in the window of opportunity with moderate-to-severe symptoms, the benefits outweigh the small absolute increases in certain risks, and the decision should rest on a clear-eyed view of both rather than reflexive avoidance.

Some situations change the standard approach. Surgical menopause, from removal of both ovaries, causes an abrupt, severe drop in estrogen with intense symptoms and faster bone loss than natural menopause. HRT is usually strongly recommended for women who have this before the natural menopause age, unless there's an absolute contraindication, and is continued at least to around age 51 to replace what the body would otherwise have made. The benefit-risk balance is more favourable here because you are replacing, not adding.

Premature ovarian insufficiency (POI), where menopause happens before 40, similarly carries a strong recommendation for HRT until at least the natural menopause age, with combined oral contraceptives sometimes used as an alternative in younger women, especially if contraception is also needed. The bone, heart, mood and cognitive benefits of estrogen during those years are substantial. The condition is covered fully in the guide to primary ovarian insufficiency in India. Early menopause between 40 and 45 sits in between and generally also favours HRT.

Breast cancer history is the most delicate scenario. Recent, active or recurrent breast cancer is generally a contraindication to systemic HRT. Survivors well past completed treatment with no evidence of disease usually try non-hormonal options first; for severe symptoms that don't respond, systemic HRT may occasionally be considered after an individual discussion with breast oncology, and low-dose vaginal estrogen for vaginal symptoms has a more favourable profile and is sometimes used after oncology sign-off. Endometrial cancer history needs similar specialist input. For these complex cases the decision belongs with the relevant specialist, and many Indian metro cities now have dedicated menopause clinics that manage them routinely.

If you can't use HRT or prefer not to, there's a substantial set of alternatives. Non-hormonal medicines for hot flushes include low-dose SSRIs and SNRIs (such as paroxetine, venlafaxine or escitalopram, around 200-600 per month, cutting hot flushes by roughly half), gabapentin (especially useful for night sweats given its evening sedating effect), and the newer neurokinin-3 antagonist fezolinetant, now entering Indian specialist clinics. These are discussed in detail in the guide to hot flush relief.

For vaginal symptoms, low-dose vaginal estrogen, with minimal absorption into the bloodstream, suits most women, including many who can't use systemic HRT, alongside vaginal moisturisers and lubricants. For bone protection, bisphosphonates (alendronate, risedronate, zoledronic acid) are first-line where osteoporosis or high fracture risk is established, supported by adequate calcium intake and correcting vitamin D deficiency, which is very common in Indian women. For low mood, the antidepressant and talking-therapy options in the menopause mood changes guide apply.

Complementary and traditional Indian approaches include Ayurvedic menopause preparations (Menosan, M2-Tone, Shatavari formulations, with limited evidence but acceptable safety from reputable manufacturers), phytoestrogen-rich foods (soy, flaxseed, chana), adaptogens such as ashwagandha for anxiety, and yoga, pranayama and meditation, which have reasonable evidence for symptoms and quality of life. The honest position is that for severe symptoms HRT is the single most effective intervention, while the non-hormonal route usually means combining several approaches to reach similar relief. For mild-to-moderate symptoms the alternative pathway is more likely to be enough. The right choice depends on your symptom severity, any contraindications, your preferences and access.

Speak to a gynaecologist or menopause-aware doctor before starting HRT, and sooner rather than later if symptoms are disrupting your sleep, work or relationships, since effective help exists. Once on HRT, get medical advice promptly for any of the following warning signs.

Seek urgent care for sudden chest pain or breathlessness, pain, swelling or redness in one calf (possible clot), sudden severe headache, weakness or numbness on one side, or trouble speaking or seeing (possible stroke). Book a non-urgent but timely review for any new breast lump, skin dimpling or nipple change; any vaginal bleeding after menopause or unexpected heavy or persistent bleeding on HRT; severe or persistent headaches, especially migraine with aura; or yellowing of the skin or eyes. Don't quietly stop or change your dose on your own; ask your doctor, who can usually adjust the regimen to fix side effects while keeping the benefit.

• The 2022 Hormone Therapy Position Statement of The North American Menopause Society
• Indian Menopause Society — Clinical Practice Guidelines on Menopause
• NICE Guideline NG23: Menopause — diagnosis and management
• ACOG: Hormone Therapy for Menopausal Symptoms
• Women's Health Initiative — Hormone Therapy Trials Overview (NHLBI)